comparemela.com
Home
Live Updates
Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors : comparemela.com
Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has
Related Keywords
United States ,
Sant Chawla ,
Michaelv Morabito ,
Pankaj Mohan ,
Richard Kenney ,
Exchange Commission ,
Principal Investigator At Sarcoma Oncology Center ,
Sonnet Biotherapeutics Inc ,
Securities Exchange ,
Sonnet Biotherapeutics Holdings Inc ,
Nasdaq ,
Fully Human Albumin Binding ,
Chief Medical ,
Sonnet Founder ,
Chief Executive ,
Principal Investigator ,
Sarcoma Oncology Center ,
Securities Act ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
Jsonnet ,
Iotherapeutics ,
Nnounces ,
First ,
Patient ,
Hosed ,
Hase ,
Linical ,
Trial ,
010 ,
Dvanced ,
Olid ,
Rumors ,
comparemela.com © 2020. All Rights Reserved.